~!!~Seres Therapeutics last released its quarterly earnings results on Thursday, August 6th// The company reported EPS for the quarter, missing analysts* consensus estimates of ($0//30) by $1//15// The firm*s revenue was down 100//0% on a year~over~year basis// Equities analysts predict that Seres Therapeutics will post $1//69 EPS for the current year//©
~!!~A number of analysts have recently weighed in on the company// Canaccord Genuity began coverage on Seres Therapeutics in a report on Wednesday, July 22nd// They issued a **buy** rating and a $50//00 target price on the stock// Zacks lowered Seres Therapeutics from a **hold** rating to a **sell** rating in a report on Tuesday, September 22nd// Bank of America started coverage on shares of Seres Therapeutics in a research note on Tuesday, July 21st// They set a **neutral** rating and a $51//00 target price for the company// Leerink Swann began coverage on shares of Seres Therapeutics in a research report on Tuesday, July 21st//